Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
about
Second-generation antipsychotics and extrapyramidal adverse effectsAnticholinergics versus placebo for neuroleptic-induced parkinsonismAnticholinergics (various) for neuroleptic-induced parkinsonismZotepine versus placebo for schizophreniaAmisulpride versus other atypical antipsychotics for schizophreniaIn Vitro and In Vivo Characterization of the Alkaloid NuciferineBinding of Sulpiride to Seric Albumins.Effectiveness evaluation of a pharmacist-driven monitoring database for tardive dyskinesia.Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.Is schizophrenia a dopamine supersensitivity psychotic reaction?Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics.Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based studyNeurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol AdministrationHaloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia.First-generation antipsychotics: not gone but forgotten.Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design.A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy.Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study.Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis.Preventive strategies and potential therapeutic interventions for delirium in sepsis.Bifeprunox versus placebo for schizophrenia.Real-world risk of diabetes with antipsychotic use in older New Zealanders: a case-crossover study.Manual Dexterity in Schizophrenia-A Neglected Clinical Marker?Living with antipsychotic medication side-effects: the experience of Australian mental health consumers.Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors.Lack of tolerable treatment options for patients with schizophrenia.Gingival pain: an unusual side effect of ziprasidone.Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.Psychotropic prescriptions for the treatment of schizophrenia in an outpatient clinic.Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service.Motor skills, cognition, and work performance of people with severe mental illness.Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users.Australian case managers' perceptions of mental health consumers use of antipsychotic medications and associated side-effects.Psychotropic drug therapy in patients in the intensive care unit - usage, adverse effects, and drug interactions: a reviewAustralian mental health staff response to antipsychotic medication side effects – the perceptions of consumers
P2860
Q21284676-388C7539-EE2F-4478-80E5-CA61312576C1Q24194301-559ED1F5-8338-4A68-82E2-07613A9A04ACQ24194831-41EB16C5-D96B-4B98-BD84-C180AA9D1D5DQ24201659-4983D10D-4E4A-417E-A03E-04092EB4B398Q24240433-E06A18D2-ACE5-464D-A8CB-7E129A9DC2D0Q28550683-EDD38E9A-3AB3-494F-9EE5-EC29A43098D1Q30383282-3032F56A-793A-44C4-8C47-F2D375F12388Q33774764-3D683857-F230-4138-9421-E742613D2365Q34048566-0C025354-A3CB-4DF0-A4F6-54D3CBCF740FQ34112026-E7298D61-AB52-4781-9246-C62E33542F8CQ34377871-58E9FFFB-277C-4951-8F44-0B54E963B43BQ34388086-8D339EB2-3F3C-4C34-8E10-5A34D153BEE6Q34734083-354CDD29-406F-4F88-9F65-1908FAD83D4BQ35987580-3FEDC44E-A2FD-4856-B0C0-097A523DC76AQ36727009-072C1858-53AF-4B78-ADD6-D83C7821FC95Q36756458-3427705F-30EB-4B71-B154-FA99B6372B4FQ38079668-1A506DB1-A8B9-4279-97C1-C9FFE18508B6Q38233228-27C6D43F-B9BC-4FED-934A-626010AAD4D9Q38306593-68907477-E9F5-48F5-B0EF-9EAEBD47A3D7Q38545655-3931055E-EEB0-4810-A3A3-46F6087D1AC6Q38642322-61C60682-2B20-4629-807C-EFD7F37BDE3EQ38672583-B6BB17F6-45AE-42AE-98CE-F35DB5FC4FCCQ38862634-084A47D6-868F-49FF-8E6B-C022F9E9571AQ38978909-44DF4B96-9079-45FF-B248-5511B9086AD3Q40457990-AB1B0E5D-2E55-4243-8130-7B2BA7D52E23Q40963897-85DCAED3-6A4B-40F5-BFFF-5FD16E6B56C1Q41662678-7D282977-3DCF-47DB-AAD8-FA8C9CB8D3D2Q41859643-9A64BB30-BB8A-40E8-9931-C562EA002972Q42120078-CE0BC589-214E-4E0A-85D4-1730CF8F7699Q43222469-B746F0A7-3442-41E2-96E5-C3734761A056Q46145089-D2E6084A-3F5F-4038-9574-1B416987325CQ46564630-EFAC87C2-55CF-4D32-A09A-690EFA1C242AQ47554728-C967B252-FF35-49DA-A886-BF023F690E03Q47556598-FF4F7371-164E-4B1E-AAE6-BF61E9AFD934Q47618934-0DEAC07E-6AC3-42C4-89AE-95B47F065F73Q47707388-6B2B4286-5E41-4EAD-85E6-64094C4764D5Q48299118-0B4C26FD-53E5-405B-B2E7-8F8BECB9B88DQ50599687-6B7745CF-69D7-478E-945C-AFF90D80AAE0Q57490627-19836092-0866-48F8-A7B9-F0B8F5D1C236Q58300632-FD4BA9D5-CA2F-4EF3-99BE-CBB599B513F5
P2860
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
@ast
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
@en
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
@nl
type
label
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
@ast
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
@en
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
@nl
prefLabel
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
@ast
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
@en
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
@nl
P3181
P1476
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
@en
P2093
Michael J Peluso
Thomas R E Barnes
P304
P3181
P356
10.1192/BJP.BP.111.101485
P407
P577
2012-03-22T00:00:00Z